NattoPharma to Hold Shareholder Informational Session and Capital Market’s Day
Timing of events, to be held on separate dates, will allow for increased exchanges during 2017
OSLO, NORWAY (26 April 2017) – NattoPharma announces it will hold a Shareholder Informational Session and a second event, Capital Market’s Day, during 2017. Both are in support of NattoPharma’s commitment to increase its communication with shareholders, including its operating and financial performance, significant news events, and updates on the company’s vision and strategy going forward.
The company will hold the Shareholder Informational Session in conjunction with its Annual General Meeting (AGM). Both the Shareholder Informational Session and the AGM will be held at the company’s corporate headquarters in Oslo. Following the summer months, NattoPharma will then hold another dedicated event, the Captial Market’s Day, where the company will provide additional details and updates on major strategic elements.
“The decision to now hold two events is driven by our desire to increase our communication and interaction with shareholders,” says Daniel Rosenbaum, NattoPharma CEO. “However, with multiple consequential initiatives currently in process, a second event after the summer will not only provide an oppourtunity to have further interactions with our shareholders, but at the same time the timing should allow us to share significant, substantive updates.”
The Shareholder Informational Session will be held on Monday, May 15th at 13:00 h. The session will include a presentation followed by a question and answer period. The AGM will begin at 15:00, as previously announced. The company is targeting a date for the Capital Market’s Day after the summer, with a specific date communicated in the coming months. In the meantime, the company is looking forward to the planned sessions in May, and the opportunity to share updates on progress to date and the compelling path ahead.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and
international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com or menaq7.com.
For more information, please contact:
• Dan Rosenbaum, CEO
E-mail: Daniel.rosenbaum@nattopharma.com
• Kjetil Ramsoy, CFO
E-mail: kjetil.ramsoy@nattopharma.com
Tags: